OBJECTIVE: To evaluate the efficacy and tolerability of the P receptor modulator CDB-2914 (Ulipristal, CDB). DESIGN: Randomized, placebo-controlled double-blind clinical trial. SETTING: Clinical research center. PATIENT(S): Premenopausal women with symptomatic uterine fibroids. INTERVENTION(S): Once-daily oral CDB (10 or 20 mg) or placebo (PLC) for 12 weeks (treatment 1). A second 3-month treatment with CDB (treatment 2) was offered. A computer-generated blocked randomization was used. MAIN OUTCOME MEASURE(S): Magnetic resonance imaging (MRI)-determined total fibroid volume (TFV) change was the primary outcome; amenorrhea and quality of life (QOL) were secondary end points. RESULT(S): Treatment 1 TFV increased 7% in the PLC group, but decreased 17% and 24% in the CDB10 and CDB20 groups. The TFV decreased further in treatment 2 (-11%). Amenorrhea occurred in 20/26 women taking CDB and none on PLC. Ovulation resumed after CDB. Hemoglobin improved only with CDB (11.9 ± 1.5 to 12.9 ± 1.0 g/dL) as did the Fibroid QOL Questionnaire symptom severity, energy/mood, and concern subscores, and overall QOL scores. The CDB was well tolerated, with no serious adverse events. Adverse events were unchanged during treatments. CONCLUSION(S): Administration of CDB-2914 for 3-6 months controls bleeding, reduces fibroid size, and improves QOL. Published by Elsevier Inc.
RCT Entities:
OBJECTIVE: To evaluate the efficacy and tolerability of the P receptor modulator CDB-2914 (Ulipristal, CDB). DESIGN: Randomized, placebo-controlled double-blind clinical trial. SETTING: Clinical research center. PATIENT(S): Premenopausal women with symptomatic uterine fibroids. INTERVENTION(S): Once-daily oral CDB (10 or 20 mg) or placebo (PLC) for 12 weeks (treatment 1). A second 3-month treatment with CDB (treatment 2) was offered. A computer-generated blocked randomization was used. MAIN OUTCOME MEASURE(S): Magnetic resonance imaging (MRI)-determined total fibroid volume (TFV) change was the primary outcome; amenorrhea and quality of life (QOL) were secondary end points. RESULT(S): Treatment 1 TFV increased 7% in the PLC group, but decreased 17% and 24% in the CDB10 and CDB20 groups. The TFV decreased further in treatment 2 (-11%). Amenorrhea occurred in 20/26 women taking CDB and none on PLC. Ovulation resumed after CDB. Hemoglobin improved only with CDB (11.9 ± 1.5 to 12.9 ± 1.0 g/dL) as did the Fibroid QOL Questionnaire symptom severity, energy/mood, and concern subscores, and overall QOL scores. The CDB was well tolerated, with no serious adverse events. Adverse events were unchanged during treatments. CONCLUSION(S): Administration of CDB-2914 for 3-6 months controls bleeding, reduces fibroid size, and improves QOL. Published by Elsevier Inc.
Authors: M C Batista; T P Cartledge; A W Zellmer; M J Merino; C Axiotis; D L Loriaux; L K Nieman Journal: Am J Obstet Gynecol Date: 1992-07 Impact factor: 8.661
Authors: G Bianchi; S Costantini; P Anserini; G Rovetta; P Monteforte; M V Menada; L Fagà; L De Cecco Journal: Maturitas Date: 1989-09 Impact factor: 4.342
Authors: Steve H Eisinger; Julietta Fiscella; Thomas Bonfiglio; Sean Meldrum; Kevin Fiscella Journal: Eur J Obstet Gynecol Reprod Biol Date: 2009-07-07 Impact factor: 2.435
Authors: James H Segars; Estella C Parrott; Joan D Nagel; Xiaoxiao Catherine Guo; Xiaohua Gao; Linda S Birnbaum; Vivian W Pinn; Darlene Dixon Journal: Hum Reprod Update Date: 2014-01-08 Impact factor: 15.610
Authors: Sinnie Sin Man Ng; Soledad Jorge; Minnie Malik; Joy Britten; Szu-Chi Su; Charles R Armstrong; Joshua T Brennan; Sydney Chang; Kimberlyn Maravet Baig; Paul H Driggers; James H Segars Journal: J Clin Endocrinol Metab Date: 2019-03-01 Impact factor: 5.958
Authors: James A Simon; William Catherino; James H Segars; Rick E Blakesley; Anna Chan; Vilma Sniukiene; Ayman Al-Hendy Journal: Obstet Gynecol Date: 2018-03 Impact factor: 7.661
Authors: Nichole M Barker; David A Carrino; Arnold I Caplan; William W Hurd; James H Liu; Huiqing Tan; Sam Mesiano Journal: Reprod Sci Date: 2015-09-29 Impact factor: 3.060